In the rat, shikimate was metabolized and excreted as hippurate, hexahydrohippurate, 3,4,5,6-tetrahydrohippurate, t-3,t-4-dihydroxycyclohexane-r-1-carboxylate and c-3,t-4-dihydroxycyclohexane-r-1-carboxylate, conjugates of catechol and CO2. The metabolism was entirely dependent on various initial microbial transformations in the gut, metabolite formation being suppressed in animals pretreated with antibiotics. Shikimate was not metabolized by mammalian tissues, and products of microbial metabolism were excreted either unchanged or after further biotransformation in the animal tissues.
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Although there is considerable information on the plant biochemistry of shikimate [(-)-3a,4a,5fl- trihydroxycyclohex-1-enecarboxylic acid] (Bohm, 1965; Haslam, 1974) , little is known of the mammalian metabolism of this ubiquitous plant acid and its many close relatives, such as quinic acid. Claims that shikimate is a mutagen and carcinogen (Evans & Osman, 1974; Evans, 1976) have added to the need for a further study of the metabolism of this compound, especially since the chemical structure of shikimate does not suggest that it is a potential toxin, even less a carcinogenic compound. This renewed interest in shikimate has prompted both a review (Stavric & Stoltz, 1976) and initial metabolic studies with rat gastrointestinal micro-organisms (Brewster et al., 1976) .
Shikimic acid or quinic acid administered orally to animals gives rise to increased urinary excretion of hippurate (Cotran et al., 1960; Asatoor, 1965; Adamson etal., 1970; Indahl & Scheline, 1973) , which may be inhibited by treatment with antibiotics. The shikimate is metabolized by gastrointestinal microorganisms to cyclohexanecarboxylate, and the latter is aromatized and conjugated with glycine in mammalian tissues (Brewster et al., 1976 (Brewster et al., , 1977a (Brewster et al., 1977b) .
Animals
Male Wistar albino rats (220-250g) were used. Where necessary, the gastrointestinal microflora were suppressed by administration of a solution of neomycin (40mg) and tetracycline (20mg) in 0.25ml of water (twice daily for 4 days, and once on the fifth day 1-2h before the experiment).
Studies in vivo
Animals were maintained in glass metabolism cages (Jencons Scientific, Hemel Hempstead, Herts., U.K.) and urine and faeces were collected separately for 24h; CO2 was collected by drawing through a series of ethanolamine/2-ethoxyethanol (1:4, v/v) solvent traps at a rate of 200cm3/min. Each animal received 100mg (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) uCi) of ['4C] shikimate/kg body wt. in 0.5 ml of water as vehicle.
To permit direct collection of urine and bile, ureters and bile ducts were cannulated (Brewster et al., 1977b Incubation of test compounds with samples of rat caecal or faecal micro-organisms was carried out essentially as described by Scheline (1966) . The incubation medium contained 0.55% (w/v) each of D-glucose, proteose peptone (Difco Laboratories) and yeast extract (Difco Laboratories) in 0.1 Msodium phosphate buffer, pH 7.4. Anaerobic incubation in lOml at 37°C for 48h was begun after addition of 0.5 ml of a 10 % (w/v) suspension of caecal contents or homogenized fresh rat faeces, both prepared in the phosphate buffer. Acidified incubation mixtures (pH 1) were extracted with 3 x lOml of either ethyl acetate or diethyl ether.
Measurement of radioactivity
Radioactivity was determined in an LKB 1210 or a Packard 3320 liquid-scintillation counter. Three scintillation systems were used: (1) 0.55% 2,5-diphenyloxazole in Synperonic NXP (I.C.I., Billingham, Cleveland, U.K.)/toluene (1:2, v/v) (Wood etal., 1975) ; (2) counted for radioactivity in scintillant 2 (lOml). Bile (50pl) was counted directly for radioactivity in scintillant 1 (4ml), and samples (50,ul) of cell-free perfusate, prepared as described previously (Brewster etal., 1977c) , were suspended in scintillant 1 (0 ml). (Lugg & Overall, 1948) . Shikimate and other 1,2-diols were detected by spraying chromatograms lightly with 0.01 Msodium metaperiodate, followed (after 5 min) by a solution of 0.9% (w/v) soluble starch, 0.8% (w/v) KI and 0.9% (w/v) boric acid in saturated sodium tetraborate (Metzenberg & Mitchell, 1954) . Compounds oxidized by periodate gave white spots against a blue background.
Solvent extractionof samples
Radioautographs of thin-layer chromatograms were produced on medical X-ray films (BB54; 18cmx24cm; Kodak, Hemel Hempstead, Herts., U.K.) by contact exposure for suitable periods of time (1-14 days).
Mass spectrometry
Electron-impact mass spectra were recorded on an AEI MS12 mass spectrometer by using direct sample insertion. Spectra were recorded at 70eV with a source temperature of 200-250°C.
For identification of metabolites 1-3, ethyl acetate extracts of urine were chromatographed with solvent system A, the metabolites located by radioautography, then removed, eluted with methanol and chromatographed individually in solvent system B. The required radioactive zones were prepared for analysis by the technique of Rix et al. (1969) .
Metabolite 4 was purified from the decolorized methanolic extracts of freeze-dried faeces (see above) from three normal rats. The extracts were subjected to preparative-layer chromatography in solvent system B. The metabolite was located, eluted, acidified with HCI (5p1) and subjected to t.l.c. in solvent systems C, D and E, applied sequentially. The purified material was acidified with HCl (5,u1) in water (1 ml) and freeze-dried.
A methanolic solution (5 ml) of metabolite 4 (a carboxylic acid) was esterified by addition of an excess of ethereal diazomethane and the resulting esters were purified by t.l.c. in solvent system F. Vol. 170 Suspected cis-1,2-diols (metabolite 4a) were esterified and purified as above, the diol esters being removed from the t.l.c. plates and eluted with methanol. After evaporation of the methanol under N2, residues (50-2004ug) were left for 24h in acetone (300,u1) containing catalytic amounts (10-100,ug) of ptoluenesulphonic acid. The acetone solution was subjected to t.l.c. in solvent system F and acetonide derivatives were removed and eluted with acetone.
Samples were then prepared for direct-insertion mass spectrometry as described above.
Metabolite 5, believed to be unchanged shikimate, was isolated from the methanolic extract of freezedried urine (see above). This was chromatographed as 5cm bands in solvent system B. The required radioactive zones were located, eluted and acidified as described above and chromatographed in solvent system C. Finally, the radioactive zones were removed and eluted with methanol into small conical glass vials for derivative formation with hexamethyldisilazane (20,u1) and chlorotrimethylsilane (10,ul) in acetone (300,ul Shikimate (metabolite 5) and metabolites 1, 2 and 4 were determined by quantitative radioassay after separation on t.l.c. Radioactive metabolites, located by radioautography, were removed and counted for radioactivity in scintillant 2 (4ml).
Results
After administration of ['4C]shikimate to rats, over 95% of the radioactivity was excreted in the urine, faeces and expired air within 24h (Table 1) . After intraperitoneal administration all of the dose was excreted in the urine, whereas after oral dosing approximately equal amounts were recovered in urine and faeces. In animals pretreated with a combination of neomycin and tetracycline, the urinary excretion of radioactivity after oral administration was greatly decreased. Oral administration of ['4C]shikimate to normal rats gave a more complex metabolic profile with 40-57% of the radioactive dose eliminated in the urine, 45-63 % in the faeces, and 4-7 % as CO2. Ethyl acetate extracts of the urine contained 34-40% of the dose, which was present as metabolites 1-3 (Fig. 1) . These metabolites were identified by t.l.c. and mass spectrometry as being (1) hexahydrohippurate (MI, mle 185), (2) 3,4,5,6-tetrahydrohippurate (M+, mle 183) and (3) hippurate (M+, mle 179) (Table 2) , and were present in amounts equivalent to 0.8-1.3 %, 2.0-3.5 % and (Table 3) 21-30% ofthe dose respectively. Analysis of whole urine revealed the presence of three further metabolites (4, 5 and 6). These were shikimate (5), confirmed by mass spectrometry of the tetrakis(trimethylsilyl) derivative (M+, m/e 462) (Table 2), catechol (6), confirmed by reverse isotope dilution of hydrolysed urine and t.l.c., and a hitherto unknown metabolite (4; see below). These metabolites were present in amounts equivalent to 8-12%, 0.6-1.9% and 2.3-3.2% of the radioactive dose respectively. The radioactivity present in the faeces (45-63% of the dose) of these animals was identified as unchanged shikimate (7.1-14.0% of the dose) and metabolite 4 (27.4-35.0% of the dose), together with small amounts (5-9% of the dose) of at least two further unknown metabolites.
Pretreatment of animals with antibiotics affected the metabolic profile greatly, with most of the radioactivity (75-81 % ofthe dose) now being excreted in the faeces. Much of this was in the form of unchanged shikimate (58-71 % of the dose), the remainder being metabolite 4 (2-5% of the dose). Urinary excretion was decreased to 12-16 % of the dose, comprising unchanged shikimate (8-12 % of the dose), hippurate (1-2 % of the dose) and metabolite 4 (0.2-0.5 % of the dose). Catechol, tetrahydrohippurate and hexahydrohippurate were barely detectable.
Metabolism in vitro
The perfusion of isolated rat livers with shikimate resulted in no detectable uptake of radioactivity from the perfusate. Trace amounts (<0.8 % of the dose over 5 h) were excreted in bile, but these were not further investigated. Methanol extraction of the freeze-dried erythrocyte-free perfusate recovered 95-98 % of the administered dose. T.l.c. of this extract revealed a single radioactive component, which co-chromatographed with authentic shikimate, and gave a tetrakis(trimethylsilyl) derivative with a mass spectrum consistent with the structure of tetrakis(trimethylsilyl)shikimate. (Table 2) . The specificity of acid-catalysed condensations of cis-1,2-diols with acetone to form acetonide derivatives was used to characterize metabolites 4a and 4b further. Thus the methyl ester of metabolite 4a was converted into a compound with diminished chromatographic polarity and with a mass spectrum consistent with the structure of the acetonide derivative ofmethyl cis-3,4-dihydroxycyclohexanecarboxylate (Table 2 ). Metabolite 4a is therefore identified as cis-3, 4-dihydroxycyclohexanecarboxylate. The highest mle observed in the acetonide spectrum was 199
[(M-15)+], representing the direct loss of a methyl radical. Parent ions are not observed in spectra of acetonides, and molecular weights are normally calculated from the peak attributed to M-15 (Budzikiewicz et al., 1967) The methyl ester of metabolite 4b did not form an acetonide derivative under the same conditions and was recovered unchanged. Hence metabolite 4b was identified as trans-3,4-dihydroxycyclohexanecarboxylate.
Discussion
Previous studies have shown that in mammals shikimate and quinate are metabolized and excreted in the urine as hippurate (Cotran etal., 1960; Asatoor, 1965; Adamson et al., 1970; Indahl & Scheline, 1973) and conjugates of catechol (Booth et al., 1960; Indahl & Scheline, 1973; Brewster et al., 1976) . It has long been known that the gastrointestinal microflora play an important role in this metabolism and benzoate was thought to be the crucial microbial intermediate. However, the present study has shown that the mammalian metabolism of shikimate is far more complex than had been expected.
After oral administration of [(4C] shikimate to rats, hippurate was identified as the major metabolite in the urine, together with small amounts of cis-3,4-dihydroxycyclohexanecarboxylate, trans -3,4-dihydroxycyclohexanecarboxylate, conjugated catechol, (100) 73 (100) 55 (100) 109 (100) 105 (100) 97 (100) 97 (65) 204 (97) 83 (71) 108 (95) 77 (89) 41 (82) 44 (100) 87 (61) 69 (42) 147 (24) 41 (59) 81 (79) 135 (30) 87 (68) 41 (40) 205 (22) 130 (20) 79 (41) 106 (25) 55 (61) 138 (38) 75 (20) 111 (15) 57 (27) 134 (16) 44 (50) 156t (20) 462* (6) 185* (13) 183* (10) 179* (2) 156t (8) 97 (55) 41 (54) 55 (50) 156t (7) 43 (100) 41 (85) 57 (59) 45 (51) 199t (47) 55 (46) hexahydrohippurate, 3,4,5,6-tetrahydrohippurate and unchanged shikimate. The last-named metabolite was also present in the faeces, but the two 3,4-dihydroxycyclohexanecarboxylates together represented about 60% of the radioactivity in this fraction. In contrast, when administered by intraperitoneal injection, all the shikimate was excreted unchanged in the urine within 7h. The acid also remained unchanged in the perfusate after recirculation through isolated liver preparations for 5h. When incubated anaerobically with gastrointestinal micro-organisms, shikimate was converted quantitatively into cyclohexanecarboxylate, a compound known to be metabolized by rat liver to hippurate, 3,4,5,6-tetrahydrohippurate and hexahydrohippurate (Brewster et al., 1977c) . The 3,4-dihydroxycyclohexanecarboxylates and catechol were not detected during these incubations with microflora, nor were they further metabolized to cyclohexanecarboxylate when they were incubated under similar conditions. However, the microbial origin of these diols was confirmed by the fact that oral administration of antibiotics to rats dramatically decreased their production, the radioactive dose of shikimate then being excreted in the faeces almost entirely unchanged.
These results suggest that shikimate (I) is metabolized by gut micro-organisms to cyclohexanecarboxylate (III) and cis-3,4-and trans-3,4-dihydroxycyclohexanecarboxylates (VII and VIII) via different pathways (Scheme 1). The cyclohexanecarboxylate is then absorbed from the intestine, metabolized in the liver and excreted in the urine as hexahydrohippurate (VI), 3,4,5,6-tetrahydrohippurate (V) and hippurate (IV), as shown in previous studies (Brewster et al., 1977b,c) . Benzoyl and cyclohexylcarbonyl ,B-D-glucuronides were not detected, but this is consistent with a slow release of cyclohexanecarboxylate in the gut (Brewster et al., 1977b decarboxylation process (Scheline, 1966) . Alternatively, microbial aromatization of shikimate to protocatechuate followed by decarboxylation may account for the formation of catechol (Indahl & Scheline, 1973) and has been demonstrated for shikimate and quinate with Lactobacillus plantarum anaerobically (Whiting & Coggins, 1971 ). This could occur via enolization of 3H-shikimate derivative (IX) to 3,4,5-trihydroxycyclohexa-1,3-diene-1-carboxylate Since shikimate occurs widely in plants and fruits, all the metabolites identified during the present study might be expected to occur naturally in the excreta of many animals. Catechol and hippurate have long been known to be natural excretion products, but hexahydrohippurate also has been detected in the urine of cattle (Suemitsu et al., 1971) . The microbial conversion of dietary shikimate into cyclohexanecarboxylate followed by conjugation with glycine in animal tissues appears to offer an explanation for this observation. This mechanism is an alternative to the suggestion that hexahydrohippurate may arise from microbial reduction of benzoate or hippurate (Rho & Evans, 1975) . However, more recently, Balba & Evans (1977) , by using a cow with rumen fistula, have demonstrated the conversion of shikimate into urinary hexahydrohippurate, thus confirming our results. As yet, none of the other metabolites identified is known to occur naturally in animal excreta, although their presence is confidently predicted.
